Enliven Therapeutics, Inc.
ELVN
$18.73
-$0.08-0.43%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -28.54M | -23.18M | -23.16M | -19.95M | -22.74M |
| Total Depreciation and Amortization | 74.00K | 80.00K | 80.00K | 78.00K | 79.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 6.84M | 6.41M | 5.90M | 3.82M | 3.93M |
| Change in Net Operating Assets | -2.50M | -510.00K | 4.99M | -4.38M | -4.64M |
| Cash from Operations | -24.13M | -17.20M | -12.19M | -20.44M | -23.36M |
| Capital Expenditure | -20.00K | 0.00 | -22.00K | -2.00K | -20.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 1.45M | 727.00K | 14.85M | -33.66M | -17.87M |
| Cash from Investing | 1.43M | 727.00K | 14.83M | -33.67M | -17.89M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 234.00K | 39.97M | 1.12M | 1.81M | 90.27M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 234.00K | 39.97M | 1.12M | 1.81M | 90.27M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -22.47M | 23.50M | 3.75M | -52.29M | 49.02M |